Welcome to our dedicated page for CLOROX CO /DE/ SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOROX CO /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOROX CO /DE/'s regulatory disclosures and financial reporting.
The Clorox Company reported quarterly net sales of $1.67 billion, essentially flat year over year, while nine‑month sales fell 7% to $4.77 billion as prior‑year ERP‑related shipments were lapped. Quarterly diluted EPS rose to $1.54, but nine‑month diluted EPS declined 10% to $3.47.
Gross margin compressed to 43.2% this quarter and 42.7% year‑to‑date, mainly from higher manufacturing and logistics costs and mix, partly offset by cost savings. Selling and administrative expenses and advertising both declined in dollars and as a percentage of sales, reflecting lower transformation and incentive costs.
Clorox paid $476 million to acquire Procter & Gamble’s 20% Glad venture interest and closed the roughly $2.25 billion acquisition of GOJO shortly after quarter end. To support these transactions, notes and loans payable increased to $1.59 billion, while cash and cash equivalents rose to $1.19 billion, and the company added new committed credit facilities. The long‑running ERP and digital transformation program, totaling about $580 million, was completed in the quarter.
The Clorox Company reported mixed third-quarter fiscal 2026 results. Net sales were $1.67 billion, essentially flat year over year, while organic sales decreased 1%. Gross margin fell 140 basis points to 43.2% as higher manufacturing and logistics costs and unfavorable mix more than offset cost savings.
Diluted EPS rose 3% to $1.54, and adjusted EPS grew 13% to $1.64, helped by cost savings, lower advertising and lower selling and administrative expenses. Year-to-date net cash provided by operations was $282 million, down 59% from $687 million, mainly due to a Glad joint venture termination payment.
The company completed its acquisition of GOJO Industries on April 1, adding the Purell brand and related health and hygiene products. Clorox cut its full-year 2026 outlook, now expecting net sales to decline about 6% and organic sales to decrease about 9%. Fiscal 2026 diluted EPS is projected between $4.78 and $4.98, a 24% to 27% decline, while adjusted EPS is guided to $5.45 to $5.65, down 27% to 29%, reflecting ERP-related shipment timing, GOJO integration costs and ongoing digital investments.
Clorox Co/The ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,889,552 shares of Common Stock, representing 7.35% of the class as reported with a 03/31/2026 date. The filing lists 1,039,115 shares of sole voting power and sole dispositive power over 8,889,552 shares.
The filing is a Schedule 13G filed under passive/investment manager reporting conventions and is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Clorox Co (CLX) EVP and CFO Luc Bellet reported a routine tax-related share disposition. On vesting of restricted stock, the company withheld 244 shares of common stock at $103.63 per share to cover tax obligations, rather than selling shares in the open market.
After this withholding, Bellet directly holds 20,638 shares of Clorox common stock. Footnotes also note that this total includes 18 shares acquired through a dividend reinvestment feature under the company’s Stock Incentive Plan.
Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.
Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.
Clorox (CLX) director Russell J. Weiner reported routine compensation-related acquisitions of Deferred Stock Units. On February 13, 2026, he received 172.3630 Deferred Stock Units, and on March 31, 2026, he received 325.6779 Deferred Stock Units, each on a 1-for-1 basis linked to Clorox common stock.
According to the footnotes, some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and others in lieu of quarterly director fees. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director. Following these awards, his reported balance is 18,004.0034 Deferred Stock Units held directly.
Clorox director Pierre R. Breber reported routine compensation-related awards of Deferred Stock Units tied 1-for-1 to Clorox common stock. On March 31, 2026, he acquired 325.6779 Deferred Stock Units, bringing his holdings to 3100.0674 units. On February 13, 2026, he had received an additional 27.0502 units.
According to the disclosures, some Deferred Stock Units were acquired through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan and some were received in lieu of quarterly director fees. These units will be settled entirely in Clorox stock when Breber retires or otherwise leaves the board, and do not reflect open-market buying or selling.
Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.
The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.
Clorox director Stephanie Plaines reported awards of deferred stock units that increase her equity-based compensation stake. She acquired 265.3672 deferred stock units on March 31, 2026 and 72.7316 units on February 13, 2026, both at a stated price of $0.00 per unit as non-cash awards.
The units are credited 1-for-1 in relation to Clorox common stock and arise from dividend reinvestment during the fiscal year and receipt of deferred units instead of quarterly director fees under the Independent Directors' Deferred Compensation Plan. Following the latest award, she holds a total of 7,725.0486 deferred stock units, which will be settled entirely in Clorox stock upon her retirement or other termination of board service.
The Clorox Company completed its acquisition of GOJO Industries, makers of Purell, on April 1, 2026. Clorox purchased all issued and outstanding membership interests of GOJO under a membership interest purchase agreement with GOJO Industries Holdings and its shareholders. The acquired business will operate as Clorox Purell, led by President Carey Jaros, based in Akron, Ohio, with existing facilities remaining in Ashland, Cuyahoga Falls and Wooster, Ohio. Clorox describes the combination as expanding its health and hygiene portfolio and reinforcing its strategy to deliver comprehensive solutions for both consumers and institutional customers.